From translational research to improved local control and survival: The Gilbert Fletcher award lecture, Lugano, March 2000

International Journal of Radiation Oncology Biology Physics

Volumn 49, Issue 2, 2001, Pages 311-318

  Bartelink, Harry ^a,b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b Department of Radiotherapy   (Netherlands)

Author keywords

Chemotherapy; Comparative genomic hybridization; Microchip DNA arrays; Radiotherapy; Translational research

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOSTATIC AGENT; DNA; HORMONE; TAMOXIFEN;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; COMPARATIVE GENOMIC HYBRIDIZATION; CONFERENCE PAPER; GENE EXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; LUNG CANCER; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SURVIVAL;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CHROMOSOME ABERRATIONS; CHROMOSOME DISORDERS; CISPLATIN; COMBINED MODALITY THERAPY; DRUG DESIGN; FEMALE; HUMANS; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0035253323     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)01499-1     Document Type: Conference Paper

References (28)

1. Therapeutic enhancement in mice by clinically relevant dose and fractionations schedules of CDDP and irradiation
2. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer
3. Improved treated for cervical cancer
4. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma
5. Translational reserch offers individually tailored treatments for cancer patients
6. Efficacy of targeted supradose cisplatin and concomitant radiation theray for advanced head and neck cancer; The Memphis experience
7. st Annual ASTRO Meeting 1999 (Abstr. 2189)
8. Cisplatin and radiation; interaction probabilities and therapeutic possibilities
9. Monitoring of interaction products of cis-diamminedichloroplatinum (II) and cis-diammine (1,1-cyclobutanedicarboxylato)platinum (II) with DNA in cells from platinum-treated cancer patients
10. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin, and radiotherapy
11. Radiation-induced apoptosis
12. Topical application of miltefosine against skin metastases of breast cancer. Proceedings of the 28th ASCO Meeting, 1992 (Abstr. 39)
13. The role of radiotherapy in breast conserving treatment for ductal carcinoma in situ; First results of EORTC randomised phase III trial 10853
14. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
15. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers
16. How DNA microarrays and expression profiling will affect clinical practice
17. Hormonal therapy prolongs survival in irradiated locally advanced breast cancer. A European Organization for Research and Treatment of Cancer (EORTC) randomized phase-III trial
18. Adjuvant ovarian ablation versus CF chemotherapy I premenopausal women with pathological stage II breast carcinoma; The Scottish trial
19. Treatment with chemotherapy alone is inadequate for very young women with estrogen receptor positive breast cancer. Results from the International Breast Cancer Study Group (IBCSG) Trials I, II, V and VI. Proceedings of 35th Annual ASCO meeting, 1999 (Abstr. 260)
20. Zoladex and tamoxifen as adjuvant therapy in premenopausal breast cancer; a randomized study by the Cancer Research Campaign (CRC) Breast Cancer Trials Group, the Stockholm Breast Cancer Study Group, the South-East Sweden Breast Cancer Group and the Gruppo Interdisciplinare Valutazione Interventi in Oncologia (GIVIO). Proceedings of 35th Annual ASCO meeting, 1999 (Abstr. 251)
21. Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer; An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT-0101). Proceedings of 35th Annual ASCO meeting, 1999 (Abstr. 249)
22. Comparison of adjuvant therapy with tamoxifen and goserelin vs CMF in premenopausal stage I and II hormone-responsive breast cancer patients; Four year results of Austrian Breast Cancer Study Group (ASCSG) Trial 5. Proceedings of 35th Annual ASCO meeting, 1999 (Abstr. 250)
23. Towards prediction and modulation of treatment response
24. Human estrogen receptor beta-gene structure, chromosomal localization and expression pattern
25. CDK-independent activation of estrogen receptor by cyclin D1
26. Ligant-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1